TWIDH - News, Fundings and Calendar

Adding up just the disclosed USD amounts gives approximately $1.04 billion raised.

Top 3 Startups by Funding Amount:

1. ITM Isotope Technologies Munich SE €188 million ($204M)
2. Summit Therapeutics, Inc. $200 million
3. Sword Health $130 million

News

Tempus AI , which provides data and analytics tools for precision medicine, announced terms for its IPO on Wednesday.

Funding

ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, announced a €188 million ($204M) equity investment led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne to advance and expand its radiopharmaceutical pipeline, foster its development platform and prepare for potential commercial launch of its phase III lead candidate ITM-11 for treating gastroenteropancreatic neuroendocrine tumors.

Summit Therapeutics, Inc. , a Miami-based oncology company developing cancer treatments, secured $200 million in funding. An unnamed investor purchased a large stake in the company at a premium, providing capital for further development of its drug, ivonescimab, and general business operations.

Sword Health , a startup that facilitates remote physical therapy sessions and continuous monitoring through a digital platform, has raised $130 million in a funding round from investors, including Khosla Ventures, General Catalyst, BOND, and Founders Fund. This round values the company at $3 billion, representing a $1 billion increase from its previous funding round in November 2021. Sword Health also allowed its employees to sell the company's $100 million equity as part of this financing.

Vilya , a Seattle-based biotechnology company focused on developing a new class of precision medicines targeting disease biology, has expanded its Series A funding to $71M. The funding round was led by ARCH Venture Partners, with participation from NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. As part of this financing, Greg Yap, Partner at Menlo Ventures, has joined Vilya's board of directors. The raised capital will accelerate the advancement of Vilya's proprietary computational drug design and development platform and its pipeline of novel macrocycle therapeutics that precisely target disease-specific biological mechanisms. This funding will enable Vilya to further its mission of developing precision medicines through its cutting-edge computational and drug discovery capabilities.

restor3d , a Durham, NC-based company specializing in 3D-printed, personalized orthopedic implants, has raised $70M in funding. The funding consists of a $55M Series A round led by private investors, including Summers Value Partners and existing investors and an additional $15M in debt financing led by Trinity Capital. The funding will enable restor3d to further its mission of providing customized, 3D-printed orthopedic implants tailored to individual patient needs while advancing its technological capabilities and enhancing educational initiatives in the field.

ActuityMD, a Boston-based technology partner for the commercial medical technology industry, has raised $45M in a Series B funding round, bringing the total amount raised to $83M. The investment was led by ICONIQ Growth, with participation from Atreides Management, Stepstone Group, and existing investors Redpoint Ventures, Benchmark Capital, and Artisanal Ventures. ActuityMD plans to utilize the raised funds to expand its commercial intelligence platform and further its mission of accelerating the adoption of medical technologies across the healthcare industry.

Eko Health , a San Francisco-based company specializing in applying artificial intelligence for early detection of heart and lung diseases, has raised $41M in a Series D funding round. The investment was backed by ARTIS Ventures, Highland Capital Partners, NTTVC, Questa Capital, Double Point Ventures, EDBI, and LG Technology Ventures. Eko Health plans to utilize the raised funds to strengthen its presence in the U.S. market and accelerate its expansion into key international markets. Additionally, the company will expand access to its AI-enabled platform for detecting cardiac and pulmonary diseases at an early stage.

Advanced Medicine Partners , a Durham, NC-based developer of innovative advanced medicines, received an additional $32 million in financing led by Deerfield Management, with participation from ARCH Venture Partners and other investors. This latest round brings the total direct investment in Advanced Medicine Partners to $60 million since its separation from Jaguar Gene Therapy. The company specializes in process development, manufacturing, analytical development, and testing for advanced therapy products, focusing on viral vectors for gene and cell therapies. Its expertise allows it to produce best-in-class advanced therapy products and analytics tailored for viral vector-based gene and cell therapies.

Materna Medical , a Mountain View, CA-based company operating for 14 years, has raised a $20 million Series A funding round. The investment was led by InnovaHealth Partners, with participation from Wavemaker Three-Sixty Health, Kimera Limited, Women's Venture Capital Fund, Golden Seeds, Band of Angels, and Houston Angel Network. Materna Medical specializes in developing medical devices supporting women's pelvic health. This funding will enable the company to advance its innovative solutions in women's pelvic health and medical devices.

Axena Health , a medical device company focused on female pelvic health, raised $9.4 million in Series A funding. Cross-Border Impact Ventures (CBIV) led the round, which existing investors joined. The company will use the funds to expand its offerings and development efforts.

Psylo, a San Diego-based biotechnology company developing next-generation neuroplastogens, has raised $8 million in a Seed funding round. Tenmile led the round, which included participation from Palo Santo, Focalpoint Ventures (formerly Empath Ventures), Mystic Ventures, and Gaingels. The funding will be used to accelerate the advancement of PSYLO-100X, Psylo's flagship non-hallucinogenic 5-HT2A agonist, for the treatment of depression and other mental health disorders.

Raydiant Oximetry, Inc. , a clinical-stage medical device company based in San Ramon, CA, has secured $7.5M in a Series A3 Extension funding round. The investment was spearheaded by Cross-Border Impact Ventures, with participation from RH Capital, Global Health Impact Fund, VCapital, and the March of Dimes Innovation Fund. The company plans to utilize the raised capital to support two clinical studies evaluating its LumerahTM and DaisyTM technologies, which are focused on advancing maternal and neonatal health solutions.

Bioptha, a French biotech company developing treatments for eye diseases, raised €6.5 million in seed funding. Led by UI Investissement, the funds will be used to move their glaucoma treatment towards human trials and advance another program targeting macular edema, both major causes of blindness.

Sware , a Boston-based provider of a software validation solution for life sciences companies, raised $6M in Series B funding led by First Analysis with participation from existing investors to bolster the R&D of its Res_Q CSV platform with AI capabilities, streamline processes, and expand its sales team, adding First Analysis' Matt Nicklin to its board.

Eyebot , a Boston-based startup operating for three years, has raised $6 million in a funding round co-led by AlleyCorp and Uniquity Ventures. The company develops AI-powered kiosks capable of conducting eye exams in just 90 seconds without requiring an optometrist to be present. Additional investors participating in the round include Susa Ventures, Village Global, Baukunst, Ravelin, and Spacecadet. Eyebot plans to use the fresh capital to develop and scale its innovative eye exam kiosk technology further.

Spike, a two-year-old Lithuanian startup with a platform that leverages generative AI to help healthcare organizations manage and analyze large volumes of health data, has raised $3.5 million in seed funding. The investment round was co-led by Practica Capital and TheVentureCity, with additional participation from CEAS Investments, Plug & Play Ventures, Geek Ventures, and Axel Springer Porsche.

SciTech Development, Inc. , a clinical-stage oncology pharmaceutical company based in Grosse Pointe Farms, MI, has raised an additional $3.2M in funding, bringing the total amount raised to $12M. Storm Lake Capital and Pointe Angels led the latest round. The company plans to utilize the funds to advance its Phase 1b clinical trials of ST-001, a potential treatment for T-NHL (T-cell non-Hodgkin's lymphoma), and subsequent clinical trials for small-cell lung cancer.

Keragon , a Boston-based company offering an AI-powered HIPAA-compliant automation platform for healthcare, has raised $3 million in funding. The funding round was led by Focal and Afore, with participation from 25madison and Lifepoint Health. Keragon plans to utilize the funds to expand its operations and further develop its platform.

Saguaro Biosciences , a Quebec City, Canada-based company developing live cell reagents for AI-enhanced discoveries, has raised $3 million in a Seed funding round. The investment was led by AQC Capital and Anges Québec, with participation from Martin Leblanc, Co-Founder and Vice-Chairman of CellCarta Biosciences, and Investissement Quebec and Ville de Québec. The raised funds will drive the commercial expansion of Saguaro's ChromaLive? reagent platform, enabling time-sensitive imaging and AI-powered analysis of live cells. This financing will support the company's efforts to scale its innovative live cell reagent solutions and leverage AI capabilities to facilitate groundbreaking discoveries in life sciences research.

DELFI Diagnostics , a Palo Alto, CA-based developer of blood-based tests, has received an equity investment from the Merck Global Health Innovation Fund (GHIF). The amount of the deal was not disclosed. DELFI Diagnostics plans to utilize the funds to accelerate the development and commercialization of its cancer detection solutions based on analyzing circulating nucleic acids in the blood to detect and monitor cancer. This investment from Merck's GHIF will support DELFI Diagnostics in advancing its liquid biopsy technologies for earlier and more accurate detection of various cancers.

Viseon Inc. , a MedTech company based in Irvine, CA, focusing on the spine market, has raised undisclosed funding from insider investors. The specific backers were not disclosed. The financing will enable Viseon to develop its 4K-ADV? product line further and expand its market reach, focusing on several fronts where the digitization of open and minimally invasive spine surgeries can facilitate clinical and economic benefits. The funds will support Viseon's efforts to advance its technological solutions and capitalize on opportunities to digitize spine surgical procedures.

Sofie Biosciences, Inc. , a radiopharmacy and contract development and manufacturing organization based in Dulles, VA, has received a strategic growth investment from Trilantic North America. The amount of the deal was not disclosed. This investment was made in partnership with SOFIE's founding team, who will retain a significant equity stake and continue to lead the business. SOFIE Biosciences plans to utilize the funds to accelerate its growth initiatives, including expanding its production capacity and geographic presence to improve patient access to its portfolio of radiopharmaceutical products. The investment from Trilantic North America will support SOFIE Biosciences' efforts to scale its operations and enhance its ability to serve the growing demand for radiopharmaceuticals.

Solarity , a St. Louis, MO-based provider of automated clinical data processing solutions for acute and ambulatory healthcare providers, has received a strategic growth investment from TA Associates. The amount of the deal was not disclosed. Solarity's management team and existing private equity partner BV Investment Partners will retain substantial ownership stakes in the company. As part of this transaction, Ethan Liebermann, Managing Director and Co-Head of Healthcare at TA, and Eric Zagorski, Senior Vice President at TA, will join Solarity's Board of Directors. The company intends to use the funds from this investment to accelerate its organic growth strategies, bolster its technology offerings, and drive continued innovation in its software capabilities for automated clinical data processing solutions serving the healthcare industry.

Nucleus RadioPharma , a Rochester, MN-based integrated development, manufacturing, and supply chain company for radiopharmaceuticals, raised an undisclosed amount in an extended Series A funding round. AstraZeneca, GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri backed the round. Concurrent with the financing, Tyrell Rivers, PhD, Executive Director of Corporate Ventures at AstraZeneca, joined Nucleus RadioPharma's Board of Directors. The funds will expand the company's development, supply, and commercial manufacturing capabilities to make targeted radiotherapies and theranostics more accessible globally.

Mindset Medical , a Phoenix-based software as a medical device company, raised a Series A funding round led by Grayhawk Capital and Questa Capital with participation from AZ Venture Development Corporation, Amgen Ventures, and Nova Prime further to develop its Informed Vital Core non-contact physiological measurements application and conduct clinical studies to support its use as a medical device.

BranchLab , a New York City-based data science company developing advanced AI software to enable healthcare brands to reach the right consumers, raised an undisclosed seed funding round led by newark venture partners with participation from Aperiam, to accelerate product development and market expansion of its privacy-safe healthcare advertising solutions for TV.

PharmaCord , a Jeffersonville, IN-based pharmaceutical services company, received an undisclosed investment from Permira to expand its operations and business reach. Subject to regulatory approvals expected to close by Q4 2024, the company's founder and management team will remain investors alongside Permira.

Funds

Brandon Capital , a Melbourne-based life sciences venture capital firm, has launched its sixth fund, Brandon Capital Fund VI, with an initial close of US$180M. The fund's limited partners include Australian superannuation (pension) funds and new investors, and it remains open for additional investments from local and international sources. Fund VI aims to support the growth of life sciences startups and growth companies in Australia, New Zealand, the UK, Europe, and the United States. The firm provides management and investment support to guide its portfolio companies through their early growth stages.

Events

• DES – Digital Business World Congress – The international expo & congress dedicated to Digital Transformation, visited by over 18.000 C-level executives from 49 countries and over 450 speakers from all over the world, who come to acquire the crucial knowledge to shape their industries’ future. Malaga, Spain; Jun 11-13, 2024
• ConfedExpo - NHS ConfedExpo 2024 is set to be one of the UK's largest and most significant health and care conferences, attracting over 5,400 delegates over two days. The event, which NHS Confederation and NHS England deliver in partnership, will once again bring together health and care leaders and their teams. You’ll have the opportunity to network with leaders and managers who can lead and drive change in health and social care and attend many theatre sessions and learning theatres. Across two days, NHS ConfedExpo aims to share learning and best practices, encourage innovation, and provide valuable networking opportunities. Manchester, UK; Jun 12-13, 2024
• DIA – Igniting conversations at the intersection of healthcare. Engage with life sciences peers, patients, and thought leaders on the issues of today and the possibilities for tomorrow. San Diego, CA; Jun 16-20, 2024
• HLTH Europe 2024 - Building on our track record of running the US’s best health events, we're bringing the HLTH DNA to Europe. At the heart of HLTH are world-class speakers, immersive attendee experiences, incredible networking events and parties, and impactful networking programs. Amsterdam; Jun 17-20, 2024
• UX Healthcare – With Healthcare -Tech as one of the fastest-growing industries globally, how will Healthcare UX improve, adapt, and enhance patient experiences? We will discuss our UX Challenges and design the needs, not the wants, of our Users. We will look at trends globally. Are we designing for Machine learning and AI? How are we designing for Telemedicine, and will Chatbots, Messaging, and video-calling reach their potential? Amsterdam; Jun 18-19, 2024
• Medtech Live?– A unique combination of a medical technology trade fair, Congress, and partnering featuring medical technology, medical devices, medical technology research, and more. Stuttgart; Jun 18-20, 2024
• HFMA – The HFMA Annual Conference is the premier event in healthcare finance, drawing more than 3,000 participants from across the nation and offering 4 strategy-focused general sessions, more than 70 educational sessions, and 7 content tracks over 4 days. Las Vegas, NV; Jun 24-27, 2024

More Events - Healthcare Calendar

?